On January 14, 2015, Sanpower Group and Japan's Hitachi Ltd. signed a letter of intent in Tokyo to purchase the latter’s heavy ion cancer treatment system, and work together to build a heavy ion cancer treatment centre. Tian Youzhong, Executive Vice President of Sanpower Group and General Manager of Healthcare Department, Koji Tanaka, Vice President of Hitachi Ltd., Masahiro Kitano, President of Hitachi Health Care Company, etc. attended the signing ceremony.

Radiotherapy is recognised by the medical profession as one of the primary means of treating cancers. Compared with the various deficiencies existing in conventional means of radiotherapy, heavy ion cancer radiotherapy technology enables the dose distribution to relatively concentrate in cancer cells when killing the solid tumours, so that the meantime it kills cancer cells, it can greatly reduce the damage to the surrounding normal tissues and the sensitive parts. Supported by the valid treatment program in the earlier stage, the patients will suffer no significant side effects. As a result, their pains will be greatly alleviated, and their life quality improved. Presently, this advanced cancer treatment equipment and technology is mainly applied in a limited number of countries like Japan, the United States and Europe, while in China the cancer treatment market has basically been in the blank.

Founded in 1910, Hitachi is the world's renowned multinational group, with its headquarters located in Tokyo, Japan. In Japan's manufacturing sector, it is the second largest manufacturing company next only to Toyota Motor Company, as well as Japan's fourth largest company in the whole industry next only to Toyota, Japan Post, and Japan Telecom. In 2013, Hitachi's total sales reached about 9.6 trillion yen (about 590 billion yuan), ranking 78 among the world's Top 500 Enterprises. With its products covering many fields like information and telecommunications, electronics, semiconductor, industrial power, digital multimedia, raw materials, financial equipment, medical equipment, etc., the company boasts a world-leading research capability and technical level in heavy ion cancer therapy systems.

In recent years, Sanpower Group has been vigorously developing the healthcare industry, so the signing of the letter of intent marks another important step forward in the development of its domestic medical market. Hitachi said that it will provide Sanpower Group with comprehensive support to help build heavy ion treatment centre in China, so as to apply this most cutting-edge radiotherapy technology to the vast majority of Chinese patients as soon as possible.